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Abstract
Background: Mass drug administration (MDA) of praziquantel is one of the main control measures against human
schistosomiasis. Although there are claims for including pregnant women, infants and children under the age of 5
years in high-endemic regions in MDA campaigns, they are usually not treated without a diagnosis. Diagnostic
tools identifying infections at the primary health care centre (PHCC) level could therefore help to integrate these
vulnerable groups into control programmes. freeBILy (fast and reliable easy-to-use-diagnostics for eliminating
bilharzia in young children and mothers) is an international consortium focused on implementing and evaluating
new schistosomiasis diagnostic strategies. In Madagascar, the study aims to determine the effectiveness of a test-
based schistosomiasis treatment (TBST) strategy for pregnant women and their infants and children up until the
age of 2 years.
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Methods: A two-armed, cluster-randomized, controlled phase III trial including 5200 women and their offspring
assesses the impact of TBST on child growth and maternal haemoglobin in areas of medium to high endemicity of
Schistosoma mansoni. The participants are being tested with the point of care-circulating cathodic antigen (POC-
CCA) test, a commercially available urine-based non-invasive rapid diagnostic test for schistosomiasis. In the
intervention arm, a POC-CCA-TBST strategy is offered to women during pregnancy and 9months after delivery, for
their infants at 9 months of age. In the control arm, study visit procedures are the same, but without the POC-CCA-
TBST procedure. All participants are being offered the POC-CCA-TBST 24 months after delivery. This trial is being
integrated into the routine maternal and child primary health care programmes at 40 different PHCC in
Madagascar’s highlands. The purpose of the trial is to assess the effectiveness of the POC-CCA-TBST for controlling
schistosomiasis in young children and mothers.
Discussion: This trial assesses a strategy to integrate pregnant women and their children under the age of 2 years
into schistosomiasis control programmes using rapid diagnostic tests. It includes local capacity building for clinical
trials and large-scale intervention research.
Trial registration: Pan-African Clinical Trial Register PACTR201905784271304. Retrospectively registered on 15 May
2019
Keywords: Schistosomiasis, Pregnant women, Children, Mass drug administration, Praziquantel, Point of care-
circulating cathodic antigen test, Test-based schistosomiasis treatment, Cluster randomized controlled trial
Introduction
Human schistosomiasis is a neglected tropical disease
(NTD) caused by trematode flatworms [1]. Among the
NTDs, schistosomiasis ranks highest in terms of
disability-adjusted life years (3.3 million DALYs), with
more than 230 million people infected and 600 million
being at risk of infection worldwide [2]. It is of particular
public health importance in Africa where both intestinal
and urinary forms of the disease caused by Schistosoma
mansoni and Schistosoma haematobium, respectively,
are prevalent. Schistosomiasis is endemic in 76 coun-
tries, and 85% of people infected live in rural areas of
sub-Saharan Africa [3]. Madagascar is one of the most
affected countries [4]. To reduce morbidity, the WHO
recommends annual treatment of school-age children
with praziquantel (PZQ) in areas of high endemicity.
This is often put into practice via mass drug dministra-
tion (MDA) campaigns [5]. MDA strategies, however,
have some limitations: usually, MDA focuses on school-
age children, thus excluding large groups of the affected
population from treatment, such as adults, pregnant
women and children under the age of 5 years (U5) [6].
The main public health impact of Schistosoma infec-
tions is associated with chronic evolutions of the disease.
Chronic infections with S. mansoni can lead to hepatic
inflammation that progresses to advanced hepatic dis-
ease and can culminate in cirrhosis or cancer [7].
Chronic infections with S. hematobium can lead to ec-
topic pregnancy, infertility, abortion and cervical lesions
and symptoms mimicking cervical cancer (female genital
schistosomiasis (FGS)) [8]. All schistosomiasis infections
can lead to chronic, not-organ-specific symptoms such
as anaemia, fatigue and nausea. In children,
schistosomiasis manifests unspecifically but equally det-
rimental with failure to thrive. In pregnant women,
schistosomiasis may lead to anaemia.
The scientific community and WHO recognize the
need for a holistic and integrated approach as the most
effective way to tackle the disease [9]. Unfortunately, the
exclusion of adults, pregnant women, infants and U5
children from MDA leads to increased morbidity, the
perpetuation of poverty and a of schistosomiasis trans-
mission [5].
Guidelines for the treatment of schistosomiasis during
pregnancy are not yet widely implemented. After more
than 30 years of post-market experience with praziquan-
tel, no reports of serious adverse events relevant to hu-
man pregnancy have ever been published, but results
from randomized controlled trials (RCTs) assessing the
efficacy and safety of the drug within this target group
are scarce [10]. Recent recommendations of the WHO
state that schistosomiasis in pregnant women is harmful
and signifies an indication for treatment. Likewise, U5
children should be given PZQ if a Schistosoma infection
can be confirmed by a diagnostic test [5]. Effective diag-
nostics available at the primary level of care to detect in-
fection are rarely integrated within the health services of
the most affected countries [11]. Since 2008, a point of
care (POC) rapid diagnostic test (RDT) based on the de-
tection of the schistosome circulating cathodic antigen
(CCA) [10], POC-CCA, became commercially available
and is widely evaluated in various endemic settings [12–
15]. The introduction of this type of tests at the primary
level of care could address the treatment of vulnerable
groups, if its use in the context of a dedicated strategy
can be shown to be effective.
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In order to improve the diagnostic strategies for the
management of schistosomiasis in vulnerable groups, the
international consortium freeBILy (fast and reliable easy-
to-use-diagnostics for eliminating bilharzia in young
children and mothers) was initiated [16]. The freeBILy
consortium carries out two conceptually different trials,
one in Madagascar (Universities of Antananarivo and
Fianarantsoa and Centre d’Infectiologie Charles Mérieux)
and the other one in Gabon (Centre de Recherches Médi-
cales de Lambaréné) in collaboration with the Bernhard
Nocht Institute for Tropical Medicine (BNITM), the
Barcelona Institute for Global Health (ISGlobal), the
Eberhard Karls Universität of Tübingen and the Leiden
University Medical Center.
The freeBILy trial in rural Madagascar is a phase III
cluster RCT (CRCT). This CRCT aims to determine the
effectiveness of test-based schistosomiasis treatment
(TBST) using POC-CCA for pregnant women and their
infants. A cost-effectiveness analysis accompanies the
trial and compares costs and health impact associated
with TBST with the status quo. The cost-effectiveness
will generate knowledge in the context of very few eco-




The overall purpose of freeBILy in Madagascar is to in-
tegrate a POC-CCA test-based schistosomiasis treatment
(TBST) into routine maternal and child primary health
care programmes. The study investigates the effective-
ness of the strategy for controlling schistosomiasis in
young children and mothers.
Specific objectives of freeBILy in Madagascar are as
follows:
1. To assess the impact of TBST on child
development by comparing schistosomiasis-
associated growth and developmental disadvantages
among young children in TBST sites (intervention)
to those in non-TBST sites (control)
2. To examine the impact of TBST on maternal health
by comparing schistosomiasis-associated anaemia
among young mothers in TBST sites to those in
non-TBST sites
3. To evaluate the sensitivity and specificity of the
urine-based POC-CCA test for the detection of S.
mansoni infections in routine maternal and child
primary health care programmes
4. To conduct an economic evaluation of the TBST
strategy in comparison with the status quo,
including its impact on health-related quality of life
and on the capacity to perform economic activities
among pregnant and lactating women
Trial design and location
freeBILy in Madagascar is a two-armed 40-cluster ran-
domized phase III trial assessing the potential impact of
TBST on child growth and maternal haemoglobin (Hb).
The 40 study centres are located in areas of medium to
high endemicity of S. mansoni in Madagascar with 20
sites in the Itasy and Bongolava regions west of
Antananarivo and 20 sites in the Amoron’i Mania region
north of Fianarantsoa. The coordination institutions for
these centres are the universities of Antananarivo and of
Fianarantsoa (Fig. 1).
Figures 2 and 3 summarize the study design. Accord-
ing to the primary objectives, two different units of ana-
lysis exist: (i) children for whom the main outcome is
the proportion showing stunted growth at 2 years of age
and (ii) mothers for whom the main outcome is Hb level
2 years after delivery.
The units of randomization are the PHCC, called Cen-
tres de Santé de Base (CSB). There is a total of 23 CSBs
in the Antananarivo and 49 CSBs in the Fianarantsoa
study area. On the basis of the criteria listed in Table 1,
20 CSBs from the Antananarivo region (10 intervention
and 10 control arms) and 20 CSBs from the Fianarantsoa
region (10 intervention and 10 control arms) were se-
lected. In addition to these 40 randomized CSBs, two
non-randomized CSBs have been included in the trial:
one is assigned to the intervention arm (Andina) and the
other to the control arm (Imerintsiatosika). Objectives 1
and 2 are rolled out in the 40 randomized CSBs. Objec-
tives 3 and 4 are rolled out in the two non-randomized
CSB.
Study setting
freeBILy in Madagascar is being implemented into rou-
tine maternal and child primary health care pro-
grammes, which consist of ante- and post-natal care,
child routine examination and vaccination. In
Madagascar, these programmes are established at CSBs,
which are at the lowest administrative level of the health
care system providing high accessibility to the
population.
Intervention
In study centres of the intervention arm, the POC-CCA-
TBST is being implemented among pregnant women be-
tween week 20 of pregnancy and delivery and at 9
months after delivery and among their babies at 9
months of age. The urine-based POC-CCA-test is done,
and PZQ treatment is offered in case of a positive diag-
nosis. In the study centres of the control arm, no TBST
is carried out, and in case of clinical suspicion of schisto-
some infection, the participants are referred to the local
health system. At the 24 months’ time point, TBST is be-
ing applied in both arms.
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Randomization
Randomization was done at the CSB level. For
randomization, a list with the codes of the 20 CSBs in
the regions of Bongolava and Itasy (so-called
Antananarivo sites) and 20 CSBs in the region of Amor-
on’i Mania (so-called Fianarantsoa sites) was provided to
the Leiden University Medical Center (LUMC), which
randomly allocated 10 of the sites to control and 10 to
intervention arm stratified by regions. LUMC informed
the University of Antananarivo, University of Fianarant-
soa and BNITM about the randomization result.
While blinding at the CSB level is not possible, all pro-
cedures of the study and of TBST (including urine sam-
pling) are implemented at both the intervention and
control CSBs. Only the actual POC-CCA test and the
treatment of positives are exclusively done in interven-
tion sites. In the participant ID, an alphanumeric elem-
ent will define the recruitment site of the women. In
case women would change the study site during the
course of the study, the study nurses would be able to
identify the non-correspondence of the site from the
participant ID. This ensures that the randomization
scheme is kept.
Eligibility criteria
Eligibility criteria for the inclusion and/or exclusion of
candidate participants are listed in Table 2. After infor-
mation sessions at the research sites, eligibility criteria
are preliminarily assessed for interested candidate partic-
ipants. After the assessment, informed consent is
Fig. 1 Distribution of the FreeBILy study sites across the regions of Bongolava, Itasy and Amoron’i Mania in Madagascar. In A, the geographic
locations of these regions of Madagascar are depicted. In B, the full list of study sites and their distribution within the regions of Bongolava, Itasy
and Amoron’i Mania are given
Fig. 2 Cluster randomized trial study design. The CSBs, randomly allocated between intervention and non-intervention, represent the
randomization units. At the 5th or 6th month of pregnancy (T0), women will be enrolled in the study and consent for their children will be
asked. At T0 and 9 (T3) and 24 (T4) months after birth, urine samples will be collected. At delivery (T2), children will formally become part of
the study
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Fig. 3 Design of the cross-sectional study. The two non-randomized CSBs Andina and Imerintsiatosika were selected as the intervention and non-intervention
sites, respectively. At the 5th or 6th month of pregnancy (T0), women will be enrolled in the study and consent for their children will be asked. At T0, blood,
urine and stool samples will be collected. At the end of the study, the sample will be analysed with the tests described in Table 3. At 8 months of pregnancy
(T1) and 9 (T3) and 24 (T4) months after birth, urine samples will be collected. At delivery (T2), children will formally become part of the study
Table 1 Inclusion criteria for the selection of CSB (Centre de Santé de Base). For all the CSBs, the mentioned criteria were assessed
and on the basis of the best scoring the final 42 centres were selected
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requested to proceed with formal recruitment, which
will start exclusively when informed consent is properly
understood and signed by the participant. Informed con-
sent will be obtained, from the participant or legal
guardians of under 16 years old volunteers, by the study
nurses who will enrol formally the participants just after
signature.
Outcomes
The primary endpoints of the study are as follows:
1. The proportion of children showing stunted growth
(height-for-age z-value < − 2) at 2 years of age to
measure the impact of TBST on child development
2. Maternal Hb at 24 months after delivery to measure
the impact of TBST on maternal health
The secondary endpoints of the study are as follows:
1. Sensitivity and specificity of the POC-CCA test
compared to a panel of reference standard tests
(measured as part of the cross-sectional study at
non-randomized sites)
2. Women’s health-related quality of life, capacity to
work and participate in economic activities and
cost-effectiveness of the interventions
Data collection plan
The baseline visit was conducted following informed
consent and eligibility assessment. At enrolment, a
unique identifier of 12 digits was assigned to each par-
ticipant. The identifier is connected within the mother-
child tandem and will be kept identical throughout the
course of the study. Demographics and short medical
history were obtained.
All sites have the same visit schedule. The sampling
scheme is the same for the intervention and control
sites; thus, the only difference between intervention and
control sites is the TBST strategy at the intervention
sites.
A POC-CCA-TBST is scheduled in the intervention
arm at the following:
– Recruitment (5th to 6th month of pregnancy) and 9
months after delivery for the pregnant women/
mothers
– Nine months of age for the children
A POC-CCA-TBST is scheduled in both arms at the
following:
– Twenty-four months of age of children for both
mother and child
The visit schedule of freeBILy is integrated into
the mother and child care scheme offered to all
pregnant women at the CSBs in Madagascar. free-
BILy includes 5 different visits (T0, T1, T2, T3, T4)
according to the following scheme as summarized in
Table 3.
Table 2 Eligibility criteria for the selection of the participants (pregnant women and later on children). The eligibility criteria are
preliminary assessed after information sessions at the research sites. After assessment informed consent is requested to proceed
with formal recruitment upon its reception
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– T0: mother’s enrolment during the 5th or 6th
month of pregnancy. Haemoglobin is measured on-
site using the Hemocue® system, and a urine sample
is being collected (≥ 25 ml). In the TBST interven-
tion arm, the POC-CCA to test for schistosomiasis
infection is done on-site. Women who test positive
are offered (40 mg/kg) PZQ treatment. Additional
samples (Table 4) are being collected at the non-
randomized sites for the cross-sectional sub-study to
assess the sensitivity and specificity of the POC-
CCA test against a panel of reference tests described
in Table 4.
– T1: 1st follow-up, 8th month of pregnancy. Haemo-
globin is measured on-site by means of the Hemo-
cue® system.
– T2: 2nd follow-up, delivery and child enrolment.
The case report form (CRF) is completed. The new-
borns are included, unless the mother decides to
withdraw her/him from the study. Weight and
height of the newborns are measured.
– T3: 3rd follow-up, 9 months after delivery/birth.
Haemoglobin is measured for all women using the
Hemocue® system. Height and weight are measured
for all children. A urine sample is being collected (≥
25ml) from all mothers and children. In the TBST
intervention arm, the POC-CCA to test for
schistosomiasis infection is being performed on-site
for the mother and child. To test-positive mothers, a
40 mg/kg dose of PZQ treatment is offered. Test-
positive children are treated with 300 mg.
– T4: 4th follow-up, 24 months after delivery/birth.
Haemoglobin is measured for all mothers on-site
using the Hemocue® system. Height and weight are
measured for all children. A urine sample is being
collected (≥ 25ml) from all the women and children.
In both arms, the POC-CCA test for schistosomiasis
infection is being performed on-site for the mothers
and children. All positive women and children are
offered 40 mg/kg and 300 mg PZQ treatment,
respectively.
All the samples collected for further laboratory ana-
lysis at the two non-randomized centres are stored on-
site at the required temperatures and delivered to the la-
boratories within 1 week. Tables 4 and 5 summarize the
testing and the sampling schemes. The tests will be per-
formed according to standardized protocols described in
[11–15, 18–25].
Information on women’s health-related quality of life
is collected at T0, T1, T3 and T4 in a sub-sample of
women enrolled at the non-randomized centres. Infor-
mation on health system resources used for TBST is col-
lected in all the facilities by means of a simple
Table 3 Scheme of scheduled visits. T0 mothers enrolment at 5th or 6th month of pregnancy pregnancy; T1 pre-delivery follow up
at the 8th month of pregnancy; T2 delivery follow up at birth and inclusion of children; T3 follow up 9 month after delivery; and, T4
final follow up 24 months after delivery
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questionnaire administered to nurses involved in the
intervention.
Sample size and statistical analysis
The sample size was calculated in relation to the primary
child outcome proportion showing stunted growth at 2
years of age, for which a larger sample size is assumed to
be necessary than for the maternal outcome (Hb, 2 years
after delivery).
The prevalence of stunting in Madagascar is estimated
to be 40% of children under 2 years of age [26]. For our
sample size estimate, it was conservatively assumed that:
 Twenty per cent of all children at the age of 2 years
are stunted (height-for-age z-score < − 2)
 The intervention can reduce the proportion of
stunted children by 50% in infected individuals, i.e.
to observe that 10% of all children at the age of 2
years are stunted in the intervention arm.
In order to estimate the appropriate number of in-
fected individuals at 9 months of age, sample sizes with
power values of 80% and 90% were subsequently calcu-
lated using the OpenEpi tool [27]. For a power of 80%,
at least 394 infected individuals at 9 months of age
would be required and for a power of 90% 526 individ-
uals. The design effect was assumed to be 1.9 by which
the initial sample size needs to be multiplied to account
for the clustered design of the study. This leads to a
sample size of 749 for 80% power and 1000 for 90%
power.
With an annual loss to follow-up of 10% from a visit
to visit and an infant mortality rate of 4%, 86% of all
mother-infant tandems are expected to present for the
9-month visit. For the 2 years visit, a loss to follow-up of
around 10% between 9 months and 2 years is assumed,
so that around 0.86 × 0.9 = 77.4% of all mother-infant
tandems are expected to present for the 2-year visit. To
correct for loss to follow-up, we use the factor 1/0.774 =
1.3. Since our analyses only focus on women infected
with schistosomiasis, the number of women to be re-
cruited needs adjusting, considering that the expected
prevalence of 0.25 results in an additional inflation factor
of 4 leading to an inflation factor of 1.3 × 4 = 5.2.
Table 4 Scheme of scheduled visits. At T0 blood and stool samples will be collected from 1000 women, urine samples from 5200
women. At T1 capillary blood will be collected from 5200 women. At T2 no biological samples will be collected. At T3 and T4
capillary blood will be collected from all the women attending the follow-up visit, urine will be collected from all the participants
attending the follow-up visit. Considering the loss to follow up 4472 mothers and 4472 children are expected at T3 to remain in the
study and 3900 women and 3900 children at 4. UCP-CF (Up-Converting Phosphor – Consecutive Flow) antibody assay will be
performed on serum samples. Hb will be measured on capillary blood. UCP-LF-CAA (Up-Converting Phosphor – Lateral Flow) and
POC-CCA will be performed on urine samples. PCR will be performed on urine, plasma and stool samples. Microscopy will be
performed on stool samples
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We hence planned to enrol 4200 eligible pregnant
women in the 40 randomized cluster of the trial ensur-
ing a power between 80 and 90% and an additional 1000
participants for the cross-sectional sub-study in the non-
randomized sites. Based on the 40 randomized clusters
identified for this study, an average of 105 women per
cluster is needed to be recruited per cluster.
Analysis for the primary outcomes
For the main child endpoint, the proportion of stunted
children (height-for-age z-value < − 2) at 2 years will be
compared between the intervention and control arm
using the chi-square tests and t-tests. Reference stan-
dards from Madagascar as reported by the WHO [28]
will be considered in the analysis. For the maternal main
endpoint, the difference in Hb 2 years after delivery will
be compared between the intervention and control arms
using the t-tests. For all analyses, a significance level of
alpha = 0.05 is assumed. Additional analyses will be per-
formed using mixed-effects logistic and linear regression
models to account for the between-cluster variation as a
random effect. Secondary and other outcomes that are
normally distributed will be analysed in the same way.
Analysis for the secondary outcomes
To measure the sensitivity and specificity of the POC-
CCA, the test results of the 1000 urines collected at the
non-randomized sites at T0 will be compared to the re-
sults obtained from the reference panel (Table 5). Sensi-
tivity of the POC-CCA is defined as the number of
samples positive in the POC-CCA test divided by the
total number of “true” positives (according to the results
obtained from the combined panel of reference tests de-
scribed in Table 5). Specificity of POC-CCA will be the
number of sample negatives in the POC-CCA test di-
vided by the total number of “true” negatives.
Additionally, women’s health-related quality of life
scores will be compared between women in the interven-
tion and in the control arms (Wilcoxon rank-sum test will
be applied). A multivariate two-way fixed effects,
Table 5 Testing scheme by randomization group. The UCP-LF antibody assay will be performed at the designated laboratory on all
the samples collected at T0 from the women attending the visit at both intervention and control training centres. The maternal Hb
will be measured at the CSB from all the women in all the sites attending T0, T1, T3 and T4 visits. The UCP-CF CAA and the UCP-LF
CAA assays will be performed at the designated laboratory on all the samples collected at T0 from all the women in all the sites and
at T3 from all the children in all the sites. The POC-CCA test will be performed for all the women attending the T0, T3 and T4 visits
and for all the children attending T3 and T4 visits at the CSB belonging to the intervention group. The POC-CCA test will be also
performed at the designated laboratory on all the samples collected at T0 from all the women in all the sites and at T3 from all the
women and children in all the sites. PCR will be performed at the designated laboratory on all the samples collected at T0 from the
women attending the visit at both intervention and control training centres. Microscopy will be performed at the designated
laboratory on all the samples collected at T0 from the women attending the visit at the intervention training centre (one of the two
non-randomised centres)
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regression model will be used to evaluate the effect of the
intervention (while controlling for other factors) on
women’s health-related quality of life scores. Finally, the
costs of the intervention and health indicators will be used
for the cost-effectiveness analysis. A decision tree model
will be estimated and where the natural history of the dis-
ease will be represented by a Markov model. The model
will be estimated by following standard approaches (i.e.,
deterministic and probabilistic analyses will be con-
ducted). The association between women’s capacity to
work and the intervention will also be estimated using the
two-way fixed effects regression analysis, while controlling
for observable time-varying factors.
Trial governance
freeBILy was established as an international consortium
in 2018 to focus on diagnostic alternatives to inform
public health strategies to improve the management of
schistosomiasis in high-endemic countries [16]. The
Madagascar freeBILy study is being conducted under the
direction of a Trial Steering Committee (TSC), which
provides overall supervision for the trial on behalf of the
sponsor, BNITM. The day-to-day operations and man-
agement of the trial are coordinated by the Trial Man-
agement Team (TMT) on the basis of a weekly meeting.
Internal and external monitoring measures are in place
in order to ensure the proper management of the trial.
Internally, the study is being regularly monitored by des-
ignated quality management staff in the field. In
addition, at the end of the implementation phase and of
each study phase (T0 to T4), a sponsor representative
visits the study centres for monitoring purposes. The
Data Safety and Monitoring Board (DSMB) provides in-
dependent expert oversight for the trial. It receives a
monthly update of the recruitment and follow-up data
and regular reports of serious adverse events (SAE). All
possible side effects are recorded in a standardized form
available at any time at the CSB and routinely reported
to the Malagasy pharmacovigilance agency that acts as a
surveillance body for the use of PZQ in the country. All
participants are requested to wait at the CSBs for an
hour after treatment in order to provide close monitor-
ing of potential side effects. To date, the drug PZQ is
not yet registered for pregnant women and U5 children.
However, in more than 30 years of post-market experi-
ence with PZQ, no reports of serious adverse events re-
lating to human pregnancy (e.g. abortions, stillbirths or
congenital anomalies) have been published [29, 30].
Ethical considerations
freeBILy in Madagascar is being conducted in line with
the ICH (International Conference on Harmonisation)-
GCP (Good Clinical Practice) guidelines, and findings
are reported according to the Standards for the
Reporting of Diagnostic Accuracy Studies (STARD)
guidelines [31]. The study has been granted ethical ap-
proval by the National Ethics Committee of
Madagascar (ref. no 022-SANP/CERBM of 05/03/
2018) and the Ethics Committee of the Hamburg
State Medical Chamber in Germany (ref. no PV5966
of 18/03/2019). Study participation is voluntary and
on the basis of written informed consent. For preg-
nant women under the age of 16 and for children, in-
formed consent is being sought from her mother or
another legally designated representative. In all cases,
participants/legally designated representatives have the
right to refuse participation in the trial and are enti-
tled to withdraw their informed consent, freely, at any
time, without giving reasons.
Community engagement and social mobilization
Community engagement and social mobilization activ-
ities were developed to engage the local population to fa-
cilitate study enrolment and decrease the loss to follow-
up. General information sessions are being held for all
women attending antenatal care services during their
pregnancy. Discussion with local leaders was held in
order for the community to endorse the trial. An infor-
mation brochure was produced and distributed among
the leaders of all different health facilities surrounding
the study centres. Social workers met women in the
community in order to discuss the trial and remind
women of the follow-up visits. In case of participation
rejection or withdrawal from the study, a questionnaire
is being administered on a voluntary basis: this tool is
allowing the team to adapt the recruitment and follow-
up strategy in order to increase the chances of retention
and final success of the study.
Trial status
The current protocol version is 1.3 approved on 13 De-
cember 2019. The recruitment of pregnant women
started on 4 April 2019 and was finalized on 4 February
2020. The trial is currently in the phase of its third
follow-up visit in which 9-months children and their
mothers are tested and treated for schistosomiasis. The
follow-up will continue until autumn of 2022, when the
child of the last included mother-child pair will have
reached the age of 2 years. The present study aims at
measuring primary outcomes on two distinct popula-
tions: pregnant women and young children. In this view,
the whole study population is included in the study
when also children are actively part of it. For this reason,
it was decided to submit the study protocol towards the
end of the T2 visit, in order to guarantee the full inclu-
sion of the study population.
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Discussion
The overall aims of this study are to assess the potential
impact of a POC-CCA TBST strategy on maternal and
infant health and demonstrate the effectiveness of inte-
grating the strategy at the primary health care level.
MDA of PZQ is one of the main control measures
against human schistosomiasis, but the success of MDA
programmes is often hampered by low compliance with
treatment, limited drug availability and misclassification
of areas selected for MDA. Altogether, these factors lead
to only partial coverage of the population in need [32].
There are claims for including pregnant women, infants
and children under the age of 5 in high-endemic areas
in MDA; however, they are usually not treated without
diagnosis [5]. Diagnostic tools identifying infections at
the PHCC level could help to integrate these vulnerable
groups into control programmes.
Schistosomiasis is being listed as one of the neglected
tropical diseases (NTDs), and the Sustainable Develop-
mental Goals (SDGs) aim at having an elimination strat-
egy for this NTD by 2030 [32, 33]. As we move towards
elimination, and high prevalence areas may become low
prevalence areas, it may be appropriate to move away
from an MDA to a test-and-treat strategy [34]. This
study assesses different aspects of a POC-CCA TBST
strategy. We will assess if a POC-CCA TBST strategy
can improve maternal anaemia and child development
measured in terms of growth at 2 years of age. The study
will show if an immediate benefit of this strategy can be
shown for mothers and their children, who are usually
excluded from PZQ-based treatment. The cost-
effectiveness of the intervention will be assessed to sup-
port the development of national control strategies and
guidelines for the treatment and management of schisto-
somiasis. More generally, the study offers the opportun-
ity to help build capacity in conducting clinical trials in
a setting with a high prevalence of NTDs and limited ex-
perience in clinical research.
The recruitment of pregnant women ended on 4 Feb-
ruary 2020. So far, pregnant women are predominantly
showing interest in the study and in the possibility of re-
ceiving the treatment during pregnancy. Our findings
will be discussed with the local authorities in order to
promote the integration of such strategy in national
guidelines if the results will prove a positive impact on
the target populations. If results will prove the effective-
ness of the interventions, they could be easily translated
to other countries where the endemic context of schist-
somiasis is comparable to the one of Madagascar. Over-
all, our findings will contribute to an improved evidence
base for the elimination strategy of schistosomiasis.
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